TY - JOUR
KW - Adult
KW - Buprenorphine, Naloxone Drug Combination
KW - Buprenorphine/administration & dosage
KW - Female
KW - Heroin Dependence/rehabilitation
KW - Humans
KW - Male
KW - Methadone/administration & dosage
KW - Middle Aged
KW - Naloxone/administration & dosage
KW - Narcotic Antagonists/administration & dosage
KW - Opiate Substitution Treatment/methods
KW - Opioid-Related Disorders/rehabilitation
KW - Severity of Illness Index
KW - Substance Abuse, Intravenous/epidemiology/rehabilitation
KW - Treatment Outcome
KW - Young Adult
AU - J. S. Potter
AU - E. N. Marino
AU - M. P. Hillhouse
AU - S. Nielsen
AU - K. Wiest
AU - C. P. Canamar
AU - J. A. Martin
AU - A. Ang
AU - R. Baker
AU - A. J. Saxon
AU - W. Ling
A1 - 
AB - OBJECTIVE: The objective of this secondary analysis was to explore differences in baseline clinical characteristics and opioid replacement therapy treatment outcomes by type (heroin, opioid analgesic [OA], or combined [heroin and OA]) and route (injector or non-injector) of opioid use. METHOD: A total of 1,269 participants (32.2% female) were randomized to receive one of two study medications (methadone or buprenorphine/naloxone [BUP]). Of these, 731 participants completed the 24-week active medication phase. Treatment outcomes were opioid use during the final 30 days of treatment (among treatment completers) and treatment attrition. RESULTS: Non-opioid substance dependence diagnoses and injecting differentiated heroin and combined users from OA users. Non-opioid substance dependence diagnoses and greater heroin use differentiated injectors from non-injectors. Further, injectors were more likely to be using at end of treatment compared with non-injectors. OA users were more likely to complete treatment compared with heroin users and combined users. Non-injectors were more likely than injectors to complete treatment. There were no interactions between type of opioid used or injection status and treatment assignment (methadone or BUP) on either opioid use or treatment attrition. CONCLUSIONS: Findings indicate that substance use severity differentiates heroin users from OA users and injectors from non-injectors. Irrespective of medication, heroin use and injecting are associated with treatment attrition and opioid misuse during treatment. These results have particular clinical interest, as there is no evidence of superiority of BUP over methadone for treating OA users versus heroin users.
BT - Journal of studies on alcohol and drugs
C5 - Opioids & Substance Use
CP - 4
CY - United States
IS - 4
JF - Journal of studies on alcohol and drugs
N2 - OBJECTIVE: The objective of this secondary analysis was to explore differences in baseline clinical characteristics and opioid replacement therapy treatment outcomes by type (heroin, opioid analgesic [OA], or combined [heroin and OA]) and route (injector or non-injector) of opioid use. METHOD: A total of 1,269 participants (32.2% female) were randomized to receive one of two study medications (methadone or buprenorphine/naloxone [BUP]). Of these, 731 participants completed the 24-week active medication phase. Treatment outcomes were opioid use during the final 30 days of treatment (among treatment completers) and treatment attrition. RESULTS: Non-opioid substance dependence diagnoses and injecting differentiated heroin and combined users from OA users. Non-opioid substance dependence diagnoses and greater heroin use differentiated injectors from non-injectors. Further, injectors were more likely to be using at end of treatment compared with non-injectors. OA users were more likely to complete treatment compared with heroin users and combined users. Non-injectors were more likely than injectors to complete treatment. There were no interactions between type of opioid used or injection status and treatment assignment (methadone or BUP) on either opioid use or treatment attrition. CONCLUSIONS: Findings indicate that substance use severity differentiates heroin users from OA users and injectors from non-injectors. Irrespective of medication, heroin use and injecting are associated with treatment attrition and opioid misuse during treatment. These results have particular clinical interest, as there is no evidence of superiority of BUP over methadone for treating OA users versus heroin users.
PP - United States
PY - 2013
SN - 1938-4114; 1937-1888
SP - 605
EP - 613
EP - 
T1 - Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START)
T2 - Journal of studies on alcohol and drugs
TI - Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START)
U1 - Opioids & Substance Use
U2 - 23739025
VL - 74
VO - 1938-4114; 1937-1888
Y1 - 2013
ER -